Key result
Age >65 predicts ~370% higher recurrent VTE risk after unprovoked PE, alongside residual obstruction and antibodies.
RCT (n=371)
double-blind
randomised
Age, residual pulmonary vascular obstruction, and antiphospholipid antibodies are independent predictors of recurrent VTE after a first unprovoked pulmonary embolism, which may help guide the duration of anticoagulation.
Answers are grounded in this paper and cite their sources.
May support risk stratification for anticoagulation duration after unprovoked PE; leaves open need for prospective validation.
We aimed to identify risk factors for recurrent venous thromboembolism (VTE) after unprovoked pulmonary embolism. Analyses were based on the double-blind randomised PADIS-PE trial, which included 371 patients with a first unprovoked pulmonary embolism initially treated during 6 months who were randomised to receive an additional 18 months of warfarin or placebo and followed up for 2 years after study treatment discontinuation. All patients had ventilation/perfusion lung scan at inclusion ( i.e. at 6 months of anticoagulation). During a median follow-up of 41 months, recurrent VTE occurred in 67 out of 371 patients (6.8 events per 100 person-years). In main multivariate analysis, the hazard ratio for recurrence was 3.65 (95% CI 1.33–9.99) for age 50–65 years, 4.70 (95% CI 1.78–12.40) for age >65 years, 2.06 (95% CI 1.14–3.72) for patients with pulmonary vascular obstruction index (PVOI) ≥5% at 6 months and 2.38 (95% CI 1.15–4.89) for patients with antiphospholipid antibodies. When considering that PVOI at 6 months would not be available in practice, PVOI ≥40% at pulmonary embolism diagnosis (present in 40% of patients) was also associated with a 2-fold increased risk of recurrence. After a first unprovoked pulmonary embolism, age, PVOI at pulmonary embolism diagnosis or after 6 months of anticoagulation and antiphospholipid antibodies were found to be independent predictors for recurrence.
No takes yet. Share an insight, caveat, or question.
Tromeur et al. (2018) conducted an RCT in unprovoked pulmonary embolism (n=371). warfarin vs. placebo was evaluated on recurrent venous thromboembolism (VTE) (HR 4.70, 95% CI 1.78-12.40). Age >65 years, pulmonary vascular obstruction index ≥5% at 6 months, and antiphospholipid antibodies independently predicted recurrent VTE after unprovoked PE.
Synapse has enriched 10 related papers. Consider them for comparative context: